BiotechTube
Lead Discovery Siena

Lead Discovery Siena

Siena, Italy· Est.
leaddiscoverysiena.it
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Lead Discovery Siena is a private, preclinical-stage biotechnology company founded in 2015 (originating from a 2012 spin-off). It leverages a multi-faceted platform combining AI/machine learning, medicinal chemistry, and biological services to advance its own drug candidates and service client programs. The company's strategy is built on fostering local and international collaborations, with a pipeline featuring promising assets in glioblastoma and broad-spectrum antivirals, alongside a proprietary Antibody Drug Conjugate (ADC) linker technology.

OncologyInfectious DiseasesPulmonary Diseases

Technology Platform

Integrated platform combining AI/machine learning for rational drug design, computational & medicinal chemistry, biological assay services, and proprietary Antibody Drug Conjugate (ADC) linker/bioconjugation technology.

Opportunities

The growing crisis of antimicrobial resistance (AMR) and the persistent unmet need in cancers like glioblastoma present significant market opportunities for LDS's pipeline.
Its hybrid service-and-therapeutics model provides revenue stability while de-risking internal R&D, and its position within the European academic network offers a pipeline of novel biology and non-dilutive grant funding.

Risk Factors

The company faces high technical risk as all therapeutic programs are in early preclinical stages, with potential for failure in efficacy or safety studies.
As a small SME, it is highly dependent on securing consistent funding through grants, services, or investment to advance its pipeline in a competitive landscape.

Competitive Landscape

LDS competes in crowded but high-need fields: its kinase inhibitors and ADCs face competition from large pharma and biotech, while its anti-infectives vie with other AMR-focused companies. Its differentiation lies in its specific target expertise (e.g., DDX3, SFK), proprietary ADC linker tech, and integrated, academia-proximate discovery platform.

More companies in Small Molecule Drugs →More companies in Italy →